Siemens Healthineers (OTCPK:SEMH.F) 2025 Capital Markets Day November 17, 2025 08:00 AM ET Company ParticipantsJulien Ouaddour - Executive Director of Equity ResearchOliver Reinberg - Head of German Equity ResearchArthur Kaindl - Head of VarianMarc Koebernick - Head of Investor RelationsVeronika Dubajova - Managing Director and Head of Medical Technology and Healthcare Services ResearchJochen Schmitz - CFOSharon Bracken - President of DiagnosticsHassan Al-Wakeel - Director of European MedTech and Services R ...

Capital Markets Day London, November 17, 2025 Unrestricted © Siemens Healthineers, 2025 1 Unrestricted © Siemens Healthineers, 2025 Capital Markets Day 2025 Safe Harbor Statement This webcast has been provided solely for use at this meeting. By attending the meeting or accessing this webcast, you agree to be bound by the following limitations. This webcast is provided in conjunction with an oral presentation and should not be taken out of context. This webcast serves for information purposes only and the in ...

Core Insights - Microsoft has transformed from a software leader to an AI powerhouse, with a focus on healthcare AI positioning it as a strong investment opportunity for 2025 [1] - The stock is currently trading at $524, reflecting a year-to-date gain of 24.5%, prompting discussions on whether to invest now or wait for a better entry point [1] Strategic Developments - The partnership with Harvard Medical School, set for October 2025, marks a significant shift in healthcare AI development, integrating Harvard Health Publishing content into Microsoft's Copilot AI [2] - This partnership aims to reduce reliance on OpenAI while enhancing proprietary healthcare capabilities, potentially generating substantial revenue streams [2] - Microsoft processes 50 million health-related queries daily, creating a competitive data advantage [2] Financial Performance - Microsoft reported $76.4 billion in revenues for Q4 fiscal 2025, an 18% year-over-year growth, with net income rising 24% to $27.2 billion [3] - Full fiscal 2025 revenues reached $281.7 billion, with operating income increasing 17% to $128.5 billion [3] - Azure cloud revenues exceeded $75 billion annually, growing 39% in the latest quarter, significantly driven by AI services [3] Product Innovations - The launch of Dragon Copilot in March 2025 represents a breakthrough in healthcare AI, combining voice AI with ambient listening, saving doctors five minutes per patient encounter [5] - The AI Diagnostic Orchestrator unveiled in June 2025 achieved 85% diagnostic accuracy on complex cases, significantly outperforming experienced physicians [6] Competitive Positioning - Microsoft operates as a trusted enterprise partner, fostering collaborations with major health systems, which enhances its investment appeal [7] - The 20-year partnership with Epic Systems provides distribution advantages that are difficult for new entrants to replicate [7] Market Outlook - The healthcare AI market is projected to grow from $37 billion in 2024 to $187 billion by 2030, indicating a 37% compound annual growth rate [15] - Microsoft's strategic positioning and financial strength suggest a favorable risk-reward balance for immediate investment [15] Valuation Considerations - Microsoft trades at a forward price-to-sales ratio of 11.68x, above the industry average of 8.69x, justified by its accelerating Azure growth and leadership in AI [9] - Despite competition from Amazon, Google, and Oracle, Microsoft's structural advantages support its premium valuation [11]

Company Overview - Netflix is expanding its gaming offerings by bringing video games to television screens for the first time, allowing subscribers to use their phones as controllers [3][4] - The initial game lineup includes titles like Pictionary: Game Night and Lego Party, aimed at group play [4] Gaming Strategy - Netflix's gaming strategy focuses on four key areas: games for kids, party games, mainstream hits like Grand Theft Auto, and titles based on Netflix franchises such as Stranger Things [5] - The company has been investing in cloud server capacity to enhance gameplay experience as it anticipates increased traffic [5]

Group 1: Telomir Pharmaceuticals Inc - Telomir Pharmaceuticals Inc's shares rose 31% to $1.86 in pre-market trading following the release of promising preclinical study results for its lead compound, Telomir-1 [1] - The preclinical study indicated that Telomir-1 was able to reverse abnormal DNA methylation in aggressive prostate cancer models [1] Group 2: Other Stocks in Pre-Market Trading - Spruce Biosciences Inc gained 90.9% to $248.89, while C3is Inc surged 73.3% to $3.83 in pre-market trading [5] - Aptevo Therapeutics Inc increased by 40.2% to $1.98, and Galecto Inc rose 37.5% to $5.10 [5] - Datavault AI Inc surged 27.8% to $2.66, reaffirming its 2H 2025 revenue guidance of $12 million to $15 million [5] - Processa Pharmaceuticals Inc gained 27.5% to $0.36, and BTQ Technologies Corp rose 25.7% to $11.44 [5] - DBV Technologies SA gained 12.8% to $14.99 after announcing the sale of approximately $30 million of ADSs [5] - Amkor Technology Inc jumped 11.2% to $33.99, announcing an expanded investment in semiconductor packaging and testing in Arizona [5] Group 3: Declining Stocks - Society Pass Inc shares dipped 24.6% to $4.00 after a significant jump of 276% on Monday [5] - Dermata Therapeutics Inc fell 19.1% to $4.35, and Aether Holdings Inc declined 16.8% to $4.51 [5] - SANUWAVE Health Inc dipped 14.4% to $34.99, cutting its FY25 revenue guidance from $48 million-$50 million to $44 million-$46 million [5] - Lazydays Holdings Inc fell 12.3% to $2.57, while NOVONIX Ltd tumbled 12.3% to $1.57 [5] - OneMedNet Corp dipped 12.1% to $2.25 after a significant jump of 149% on Monday [5]

Company Movements - Spruce Biosciences, Inc. experienced a monumental surge, with its price jumping to $136.81, marking a 1451% increase due to the FDA granting Breakthrough Therapy Designation for its tralesinidase alfa enzyme replacement therapy for treating Sanfilippo Syndrome Type B [1][7] - OneMedNet Corporation Warrants saw its price increase by 233.17% to $0.19, related to a strategic partnership with Palantir Technologies to enhance its healthcare AI and data analytics capabilities [2][7] - OneMedNet Corporation also made notable gains, with its price escalating by 184.88% to $2.93, driven by investor optimism around its technology and the partnership with Palantir Technologies [3][7] - Society Pass Incorporated experienced a 146.18% increase in its price to $3.47, following an analyst upgrade based on the company's robust second-quarter performance and positive future outlook [4][7] - Argo Blockchain plc saw its price rise by 106.89% to $0.86, despite uncertainty over its financial future, linked to ongoing negotiations regarding a senior secured loan crucial for its recapitalization plan [5][7] Market Dynamics - The significant price movements of these companies underscore the diverse factors at play in the financial markets, including technological innovations, clinical advancements, and strategic corporate actions [6][7]

Industry Overview - The Medical Services sector is undergoing significant transformation driven by technological advancements, value-based care adoption, and a focus on patient-centric solutions and precision medicine [1] - The industry includes various service providers such as pharmacy benefit managers, contract research organizations, and healthcare workforce solution providers, moving from volume-based to value-based care [3] Market Trends - The global healthcare analytics market was valued at $53.1 billion in 2024, with a projected CAGR of 21.4% from 2025 to 2034, benefiting various stakeholders [2] - The digital health market is expected to grow at a CAGR of 9.2% from 2024 to 2028, while the big data in healthcare market is estimated to increase from $78 billion in 2024 to $540 billion by 2035, representing a CAGR of 19.20% [4] - The demand for skilled nursing professionals is surging, with a projected shortfall of over 100,000 healthcare workers by 2028, including 73,000 nursing assistants [2] Staffing Challenges - The healthcare staffing shortage is exacerbated by the aging population and the exit of frontline workers due to the COVID-19 pandemic, with WHO projecting a shortfall of 9.9 million healthcare professionals by 2030 [5] - Hospitals have seen a 15.6% increase in labor expenses per adjusted discharge compared to pre-pandemic levels due to rising labor costs [5] Nursing Care Market - The role of nurses is evolving with advancements in medical technologies, and the employment of nurse anesthetists, nurse midwives, and nurse practitioners is projected to grow 40% from 2023 to 2033 [6] Industry Performance - The Medical Services Industry has underperformed compared to its sector and the S&P 500, with a collective loss of 13.4% over the past year [10] - The industry is currently trading at a forward P/E of 14.6X, lower than the S&P 500's 21.9X and the sector's 19.3X [13] Investment Opportunities - GeneDx, CVS Health, and BrightSpring are identified as stocks with strong earnings outlooks, with GeneDx expected to have a 336% earnings growth rate in 2025 [19][20][22][26] - CVS Health is focusing on advanced technological capabilities and has projected earnings growth rates of 12.6% and 14.3% for 2025 and 2026, respectively [22][23] - BrightSpring is improving care quality and is expected to see an 82.1% earnings growth rate in 2025 [26][27]

Core Insights - Microsoft's announcement of Dragon Copilot, an AI assistant for clinical workflows, aims to transform healthcare by addressing clinician burnout and workflow inefficiencies, with a release scheduled for May 2025 [1][2] Group 1: Healthcare AI and Market Context - Dragon Copilot is introduced at a time when clinician burnout has slightly decreased from 53% to 48% between 2023 and 2024, while workforce shortages persist in the healthcare industry [2] - The solution is designed to streamline documentation, provide contextual information access, and automate clinical tasks, directly targeting ongoing challenges in healthcare [2] - DAX Copilot, a component of Dragon Copilot, has already assisted over three million patient encounters across 600 healthcare organizations in the past month, with users reporting a five-minute time savings per encounter and significant reductions in burnout feelings [3] Group 2: Financial Performance and AI Strategy - Microsoft's AI business has surpassed an annual revenue run rate of $13 billion, reflecting a 175% year-over-year increase, with Azure AI services growing 157% year over year [4] - Despite these growth figures, Microsoft's stock has only gained 1.4% over the past year, underperforming the broader Zacks Computer & Technology sector and the S&P 500 [6] Group 3: Competitive Landscape - Microsoft faces significant competition in the healthcare AI space from tech giants like Alphabet, Nvidia, and Oracle, which may constrain its market share growth and profit margins [5] Group 4: Valuation and Infrastructure Challenges - Microsoft's current valuation multiple of 9.62 times forward sales suggests limited upside potential, as it exceeds the industry average of 8.03 times and its historical median of 10.33 times [8][9] - The company has invested heavily in data center expansion, doubling its overall capacity in the last three years, but acknowledges being AI capacity-constrained through at least the third quarter of fiscal 2025 [12][13] Group 5: Investment Outlook - The Zacks Consensus Estimate for Microsoft's fiscal 2025 revenues is $276.19 billion, indicating a 12.67% year-over-year growth, while earnings are expected to reach $13.08 per share, reflecting a 10.85% increase [14] - Investors may benefit from patience as infrastructure investments are expected to yield results by late 2025, coinciding with the broader rollout of Dragon Copilot [15][16]